Rivaroxaban reduces stent thrombosis risk, study says

04/19/2013 | MedPage Today (free registration)

Adding the anticoagulant rivaroxaban to dual antiplatelet therapy decreased the chances of death and stent thrombosis among patients being treated for acute coronary syndrome, according to a study in the Journal of the American College of Cardiology. The findings were based on an analysis of a 9,631-patient subgroup of the ATLAS ACS 2-TIMI 51 trial.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC